Tag:
toremifene
Latest Headlines
Latest Headlines
Ipsen bows out of troubled toremifene pact with GTx
More than a year after GTx was hammered ($GTXI) by the FDA's rejection of toremifene and its demand for a new clinical trial of the bone loss drug, France's Ipsen has opted to bow out of its
GTx shares dive after toremifene flunks PhIII cancer trial
GTx ( NASDAQ: GTXI ) reported yesterday afternoon that its prostate cancer prevention drug failed to perform significantly better than a placebo in a late-stage trial, and the news pushed its
